Clinical Trial Update: Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the short-term effects of an SGLT2 inhibitor on divalent ion levels in autosomal dominant polycystic kidney disease, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Cantonal Hospital Graubuenden | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: RECRUITING